 |
|
|
| |
High sustained virologic response (SVR24) rates with response-guided danoprevir (DNV; RG7227) plus PegIFN alfa-2a (40KD) and ribavirin (P/R) in treatment-naive HCV genotype 1 (G1) patients: results from the ATLAS study
|
| |
| |
Reported by Jules Levin AASLD Nov 5-9 2011 SF
Norah Terrault, Curtis Cooper, Luis A Balart, Dominique G Larrey, Terry D Box, Eric Yoshida, Eric Lawitz, Peter Buggisch, Peter Ferenci, Martin Weltman,
Emily Labriola-Tompkins, Sophie Le Pogam, Isabel Najera, Denise Thomas, Greg Hooper, Nancy Shulman, Ying Zhang, Mercidita T Navarro, Chin Yin Lim, Ellen S Yetzer, Patrick Marcellin
From Jules: danoprevir is being developed being boosted by low dose, 100 mg, of ritonavir as are HIV protease inhibitors, and study results will be presented soon at a conference.
|
| |
|
|
|
|
|
